Prelude Therapeutics Incorporated
NASDAQ:PRLDBiotechnology
-$0.14 today
- Market cap
- $192.16M
- Beta
- 1.01
- P/E (TTM)
- -4.5
- EPS (TTM)
- -$0.94
Volume 0.42M
Average 0.38M
PRLD EBITDA Margin
EBITDA as a percentage of revenue.
Prelude Therapeutics IncorporatedNASDAQ: PRLD
EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026
EBITDA Margin at -218.2%
EBITDA Margin was -218.2% in Q1 FY2026. On a trailing-twelve-month basis it was -455.3%, up 1345.3 pp year over year.
What to watch
Whether EBITDA Margin reaches the consensus estimate from 2 analysts of -200.7% for the fiscal year ending Dec 2026, up from -805.5% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -218.2%+66.2 pp QoQ
- Last fiscal yearDec 2025
- -805.5%+985.9 pp YoY
- LTMMar 2026
- -455.3%+1345.3 pp YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | — | — | — |
| 1 year | +985.9 pp | +604.8 pp | -381.2 pp |
| 3 years | — | +786.7 pp | — |
| 5 years | +855.0 pp | — | |
| 10 years | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- -805.5%
- Year-over-year change
- +985.9pp
| Period | Period end | EBITDA Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | -805.5% | +985.9pp |
| FY2024 | 2024-12-31 | -1791.4% | — |
| FY2023 | 2023-12-31 | — | — |
| FY2022 | 2022-12-31 | — | — |
| FY2021 | 2021-12-31 | — | — |
EBITDA Margin vs competitors
How PRLD compares with its peers on the latest reported figures
- PRLD's LTM Mar 2026 EBITDA Margin of -455.3% is the 4th highest of the 9 companies compared; the peer median is -773.7%.
- Its year-over-year change of +1345.3 pp is the 2nd highest of 7, against a peer median of +72.6 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | -67.3% | +67.9 pp | +30.0 pp | |
| LTM Mar 2026 | -161.1% | +2125.8 pp | +792.0 pp | |
| LTM Mar 2026 | -257.0% | +77.3 pp | +319.4 pp | |
| LTM Mar 2026 | -455.3% | +1345.3 pp | — | |
| LTM Mar 2026 | -547.9% | — | — | |
| LTM Mar 2026 | -999.5% | +475.3 pp | -608.7 pp | |
| FY2025 | -2858.6% | -1048.1 pp | -2396.4 pp | |
| LTM Mar 2026 | -33540.9% | — | — | |
| LTM Mar 2026 | -142957.6% | -159600.9 pp | -131573.1 pp | |
EPRXEupraxia Pharmaceuticals Inc. | FY2025 | — | — | — |
| FY2025 | — | — | — | |
| Peer median (excluding PRLD) | -773.7% | +72.6 pp | -289.3 pp | |
Competitors are the stored peer set for PRLD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 7M | 12.14M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 1.71M |
| Gross Profit | 0 | 0 | 0 | 7M | 10.43M |
| Gross Margin | — | — | — | 100.0% | 85.9% |
| Research & Development | 86.78M | 92.89M | 103.39M | 118M | 94.3M |
| Selling, General & Admin | 26.96M | 30.65M | 28.88M | 28.72M | 22.41M |
| Operating Expenses | 113.74M | 123.54M | 132.28M | 146.71M | 115M |
| Depreciation & Amortization | 915K | 1.32M | 1.17M | 1.77M | 1.71M |
| EBITDA | (110.78M) | (114.11M) | (120.66M) | (125.4M) | (97.79M) |
| EBITDA Margin | — | — | — | -1791.4% | -805.5% |
| Operating Income | (113.74M) | (123.54M) | (132.28M) | (139.71M) | (104.57M) |
| Operating Margin | — | — | — | -1995.9% | -861.3% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 2.04M | 8.1M | 10.44M | 12.54M | 5.07M |
| Income Before Tax | (111.69M) | (115.44M) | (121.83M) | (127.17M) | (99.5M) |
| Pre-Tax Margin | — | — | — | -1816.8% | -819.6% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (111.69M) | (115.44M) | (121.83M) | (127.17M) | (99.5M) |
| Net Margin | — | — | — | -1816.8% | -819.6% |
| EPS (Basic) | (2.33) | (2.27) | (2.02) | (1.68) | (1.29) |
| EPS (Diluted) | (2.33) | (2.27) | (2.02) | (1.68) | (1.29) |
| Weighted Avg Shares | 47.6M | 47.37M | 60.36M | 75.81M | 76.96M |
| Weighted Avg Shares (Diluted) | 47.6M | 47.37M | 60.36M | 75.81M | 76.96M |
Prelude Therapeutics Incorporated
NASDAQ:PRLD
Intrinsic Alpha fair value
Locked
Current Price
$3.32
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.